Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs

JAMA. 2018 Jun 5;319(21):2167-2168. doi: 10.1001/jama.2018.3414.

Authors

Justin E Bekelman¹, Steven Joffe²

Affiliations

¹ Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
² Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.

PMID: 29710240
DOI: 10.1001/jama.2018.3414

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / economics
Antineoplastic Agents* / therapeutic use
Cost Control / legislation & jurisprudence
Drug Costs*
Drug Discovery
Drug Industry / legislation & jurisprudence*
Humans
Insurance, Pharmaceutical Services
Medicare*
Molecular Targeted Therapy*
Prescription Fees*
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents

Grants and funding

K07 CA163616/CA/NCI NIH HHS/United States